| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-11-13 | Topotarget (Denmark) Oncology Venture (Denmark) | APO010 | licensing |
Cancer - Oncology | Licensing agreement | |
| 2012-11-13 | Galecto Biotech (Sweden) Edinburgh BioQuarter (UK) | novel Galectin-3 inhibitors | fibrosis | R&D |
R&D agreement | |
| 2012-11-12 | AstraZeneca (UK) Foundation Medicine (USA) | identification of genomic alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. | R&D |
Cancer - Oncology | R&D agreement | |
| 2012-11-12 | Molecular Partners (Switzerland) Boehringer Ingelheim (Germany) | multiple DARPin® products | manufacturing |
Production agreement | ||
| 2012-11-12 | Pharmalink (Sweden) GP Pharm (Spain) | Busulipo™ (busulfan) | manufacturing |
Transplantation | Production agreement | |
| 2012-11-12 | GSK (UK) Imagine Institute (France) | new medicines | Netherton syndrome | R&D |
6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one | R&D agreement |
| 2012-11-12 | ActoGeniX (Belgium) Merck&Co (USA) | therapeutic approach to an undisclosed indication using ActoBiotics™ | undisclosed | R&D |
undisclosed | R&D agreement |
| 2012-11-09 | GSK (UK) Chiromics (USA) | novel classes of small molecules against certain biological targets | R&D |
R&D agreement | ||
| 2012-11-08 | Grunenthal (Germany) Amura Therapeutics (UK) | protease inhibitors | pain inflammation |
R&D | Inflammatory diseases - CNS diseases | |
| 2012-11-07 | Agilent Technologies (USA) Roche (Switzerland) | microarrays | services |
Services contract | ||
| 2012-11-06 | Vivalis (France), Kyoto Biken Laboratories (Japan) | cell line derived from Vivalis’ proprietary EB66® technology platform for the production of animal health vaccines | licensing |
Veterinary medicine | Licensing agreement | |
| 2012-11-05 | Curie-Cancer (France) Institut Curie (France) Harmonic Pharma (France) | studies of anti-cancer activity of molecules | breast cancer, eye cancer, lung cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2012-11-05 | CEVEC Pharmaceuticals (Germany) CCS Cell Culture Service (Germany) | transiently transfected CAP-TTM cells for cell based assay and protein production applications | licensing |
Licensing agreement | ||
| 2012-11-05 | Ziarco (UK) Pfizer (USA - NY) | portfolio of clinical, preclinical and research assets | R&D |
Allergic diseases - Immunological diseases - Inflammatory diseases | R&D agreement | |
| 2012-11-05 | Angel Biotechnology (UK) Reneuron (UK) | expansion of CTX cells, production of a GMP Drug Substance batch and associated testing | undisclosed | manufacturing production |
undisclosed | |
| 2012-11-01 | EMD Millipore, the Life Science division of Merck KGaA (Germany) Sistemic (UK) | control markers for stem cell production | R&D |
Technology - Services | R&D agreement | |
| 2012-11-01 | Ensemble Therapeutics (USA) Boehringer Ingelheim (USA) | macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim | undisclosed | R&D |
undisclosed | R&D agreement |
| 2012-10-31 | Ipsen (France) Inspiration Biopharmaceuticals (USA) | hemophilia drug candidates IB1001 (recombinant factor IX - rFIX) and OBI-1 (recombinant porcine factor VIII - rpFVIII) | acquired hemophilia A, congenital hemophilia A with inhibitors, treatment and prevention of bleeding in patients with hemophilia B | licensing |
Hematologic diseases - Genetic diseases - Rare diseases | Licensing agreement |
| 2012-10-30 | AET BioTech (Germany) BioXpress Therapeutics (Switzerland) | biosimilar adalimumab | rheumatoid arthritis, various inflammatory diseases | development |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Development agreement |
| 2012-10-30 | Ariana Pharma (France) CTC Laboratory Systems Corporation - CTCLS (Japan) | KEM® data analytics software and services technology | distribution |
Distribution agreement |
